StockNow
Calendar
Log in
U.S. Markets

Bristol Myers (BMY) announces 1st data from Zenbexus with Daratumumab, Phase 3 showed a statistically significant and clinically meaningful improvement in minimal residual disease-negative complete response rate

StockNow breaking-news AI analysis

Bristol Myers announced Phase 3 results showing Zenbexus combined with daratumumab achieved a statistically significant and clinically meaningful improvement in minimal residual disease-negative complete response rates.

1 stocks
BMYBristol-Myers Squibb Co.$61.94Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Fed

Fed's Williams (Voter) says cannot ignore persistent supply shocks; labour market is not a source of inflationary pressure, adding that tariffs generally do not produce sustained inflation

Politics

US President Trump says very productive meeting with President Xi for both the USA and China

U.S. Economy

US Durable Goods Orders (Aug MM) 0% vs. Exp. -0.4% (Prev. 1.1%)